Literature DB >> 24960162

Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.

Thomas Bertero, Yu Lu, Sofia Annis, Andrew Hale, Balkrishen Bhat, Rajan Saggar, Rajeev Saggar, W Dean Wallace, David J Ross, Sara O Vargas, Brian B Graham, Rahul Kumar, Stephen M Black, Sohrab Fratz, Jeffrey R Fineman, James D West, Kathleen J Haley, Aaron B Waxman, B Nelson Chau, Katherine A Cottrill, Stephen Y Chan.   

Abstract

Development of the vascular disease pulmonary hypertension (PH) involves disparate molecular pathways that span multiple cell types. MicroRNAs (miRNAs) may coordinately regulate PH progression, but the integrative functions of miRNAs in this process have been challenging to define with conventional approaches. Here, analysis of the molecular network architecture specific to PH predicted that the miR-130/301 family is a master regulator of cellular proliferation in PH via regulation of subordinate miRNA pathways with unexpected connections to one another. In validation of this model, diseased pulmonary vessels and plasma from mammalian models and human PH subjects exhibited upregulation of miR-130/301 expression. Evaluation of pulmonary arterial endothelial cells and smooth muscle cells revealed that miR-130/301 targeted PPARγ with distinct consequences. In endothelial cells, miR-130/301 modulated apelin-miR-424/503-FGF2 signaling, while in smooth muscle cells, miR-130/301 modulated STAT3-miR-204 signaling to promote PH-associated phenotypes. In murine models, induction of miR-130/301 promoted pathogenic PH-associated effects, while miR-130/301 inhibition prevented PH pathogenesis. Together, these results provide insight into the systems-level regulation of miRNA-disease gene networks in PH with broad implications for miRNA-based therapeutics in this disease. Furthermore, these findings provide critical validation for the evolving application of network theory to the discovery of the miRNA-based origins of PH and other diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24960162      PMCID: PMC4109523          DOI: 10.1172/JCI74773

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   19.456


  50 in total

1.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

Review 2.  PPARgamma and the pathobiology of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

3.  Silencing of microRNA families by seed-targeting tiny LNAs.

Authors:  Susanna Obad; Camila O dos Santos; Andreas Petri; Markus Heidenblad; Oliver Broom; Cristian Ruse; Cexiong Fu; Morten Lindow; Jan Stenvang; Ellen Marie Straarup; Henrik Frydenlund Hansen; Troels Koch; Darryl Pappin; Gregory J Hannon; Sakari Kauppinen
Journal:  Nat Genet       Date:  2011-03-20       Impact factor: 38.330

4.  The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.

Authors:  Michele M Hickey; Theresa Richardson; Tao Wang; Matias Mosqueira; Evguenia Arguiri; Hongwei Yu; Qian-Chun Yu; Charalambos C Solomides; Edward E Morrisey; Tejvir S Khurana; Melpo Christofidou-Solomidou; M Celeste Simon
Journal:  J Clin Invest       Date:  2010-02-08       Impact factor: 14.808

5.  miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells.

Authors:  Valentina Kovaleva; Rodrigo Mora; Yoon Jung Park; Christoph Plass; Abhilash I Chiramel; Ralf Bartenschlager; Hartmut Döhner; Stephan Stilgenbauer; Armin Pscherer; Peter Lichter; Martina Seiffert
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

6.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

Review 7.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

8.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

9.  Circulating miRNAs as potential marker for pulmonary hypertension.

Authors:  Chuanyu Wei; Heather Henderson; Christopher Spradley; Li Li; Il-Kwon Kim; Sandeep Kumar; Nayeon Hong; Alejandro C Arroliga; Sudhiranjan Gupta
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

10.  An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension.

Authors:  Jongmin Kim; Yujung Kang; Yoko Kojima; Janet K Lighthouse; Xiaoyue Hu; Micheala A Aldred; Danielle L McLean; Hyekyung Park; Suzy A Comhair; Daniel M Greif; Serpil C Erzurum; Hyung J Chun
Journal:  Nat Med       Date:  2012-12-23       Impact factor: 53.440

View more
  96 in total

1.  Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

Authors:  Thomas Bertero; Katherine A Cottrill; Yu Lu; Christina M Haeger; Paul Dieffenbach; Sofia Annis; Andrew Hale; Balkrishen Bhat; Vivek Kaimal; Ying-Yi Zhang; Brian B Graham; Rahul Kumar; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Stephen M Black; Sohrab Fratz; Jeffrey R Fineman; Sara O Vargas; Kathleen J Haley; Aaron B Waxman; B Nelson Chau; Laura E Fredenburgh; Stephen Y Chan
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

Review 2.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

3.  Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Authors:  Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

4.  Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease.

Authors:  Evgeny A Zemskov; Qing Lu; Wojciech Ornatowski; Christina N Klinger; Ankit A Desai; Emin Maltepe; Jason X-J Yuan; Ting Wang; Jeffrey R Fineman; Stephen M Black
Journal:  Antioxid Redox Signal       Date:  2019-03-19       Impact factor: 8.401

5.  Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension.

Authors:  Shohini Ghosh-Choudhary; Stephen Y Chan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Novel approaches to pulmonary arterial hypertension drug discovery.

Authors:  Yon K Sung; Ke Yuan; Vinicio A de Jesus Perez
Journal:  Expert Opin Drug Discov       Date:  2016-02-27       Impact factor: 6.098

Review 7.  The biology of circulating microRNAs in cardiovascular disease.

Authors:  Pil-Ki Min; Stephen Y Chan
Journal:  Eur J Clin Invest       Date:  2015-08       Impact factor: 4.686

8.  p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.

Authors:  Hilaire C Lam; Christian V Baglini; Alicia Llorente Lope; Andrey A Parkhitko; Heng-Jia Liu; Nicola Alesi; Izabela A Malinowska; Darius Ebrahimi-Fakhari; Afshin Saffari; Jane J Yu; Ana Pereira; Damir Khabibullin; Barbara Ogorek; Julie Nijmeh; Taylor Kavanagh; Adam Handen; Stephen Y Chan; John M Asara; William M Oldham; Maria T Diaz-Meco; Jorge Moscat; Mustafa Sahin; Carmen Priolo; Elizabeth P Henske
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

Review 9.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

10.  Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin's glucose-lowering effects.

Authors:  Cheol Hwangbo; Jingxia Wu; Irinna Papangeli; Takaomi Adachi; Bikram Sharma; Saejeong Park; Lina Zhao; Hyekyung Ju; Gwang-Woong Go; Guoliang Cui; Mohammed Inayathullah; Judith K Job; Jayakumar Rajadas; Stephanie L Kwei; Ming O Li; Alan R Morrison; Thomas Quertermous; Arya Mani; Kristy Red-Horse; Hyung J Chun
Journal:  Sci Transl Med       Date:  2017-09-13       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.